Financials

  • Market Capitalization 1.1792 B
  • Employee 6 500
  • Founded 1979
  • CEO Douglas C Bryant
  • Website www.quidelortho.com
  • Headquarter California, United States
  • FIGI BBG017TGV7M2
  • Industry Technology
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
-1.76
Preis-Umsatz-Verhältnis
0.73

QuidelOrtho Corporation

QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide. On May 8, 2020 the U.S. Food and Drug Administration issued to Quidel the first emergency use authorization for a COVID-19 rapid antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs.

Nachrichten